Imagine finishing cancer treatment only to feel completely drained for years — that's reality for millions of Europeans. A Dutch company built a smartphone app that works like a personal fatigue coach, using proven therapy techniques to help cancer patients and survivors manage their exhaustion. Think of it as a therapist in your pocket, available anytime, backed by decades of clinical research from psycho-oncology experts. The app is designed to work both on its own from the App Store and as a tool doctors can prescribe in the clinic.
Over 50% of Europe's 4 million cancer patients suffer from severe fatigue that ruins their daily lives — and for 30% of survivors, this exhaustion lasts up to 10 years after treatment ends. Traditional therapy is expensive, requires in-person visits, and cannot scale to reach millions of patients who need help managing this invisible but devastating side effect.
A market-ready mobile app (Version 3.0) for treating cancer-related fatigue, built on clinical trial data and decades of psycho-oncology research. The project delivered multilingual versions (Spanish, German), a version fully adapted for both patients and caregivers, and a commercialization strategy for the EU market.
If you are a digital health company looking to expand your therapy portfolio — this project developed a clinically validated mobile app (Version 3.0) for cancer-related fatigue that affects over 50% of 4 million European cancer patients. The app is market-ready with multilingual support (Spanish, German) and proven efficacy in both clinical and web-based settings.
If you are a hospital or cancer clinic dealing with patients who suffer from debilitating fatigue during and after treatment — this project built a digital therapy tool designed to integrate into clinical practice. It provides specialists with guidelines to help tired patients and has been tested through clinical trials to validate its effectiveness.
If you are a health insurer looking to reduce long-term care costs for cancer survivors — this project created a widely accessible digital medicine for cancer-related fatigue, which affects 30% of survivors for up to 10 years. The app-based approach could significantly reduce the need for expensive in-person therapy sessions.
The project describes a multi-faceted commercialization strategy targeting both direct consumer access (App Store) and clinical integration through healthcare providers. Specific pricing is not disclosed in the project data, but the dual-channel model (B2C via app stores and B2B via clinics) suggests tiered pricing. Contact the company via untire.me for current pricing.
Yes — the project specifically delivered Spanish and German language versions alongside the original, demonstrating active multi-market expansion. The app is designed to be easily accessible to any end user with a smartphone or tablet, making geographic scaling straightforward. The commercialization strategy explicitly targets the EU market.
The app is developed and owned by Tired of Cancer BV, a privately owned spin-out company of the Helen Dowling Institute in the Netherlands. Any licensing or partnership would need to be negotiated directly with the company. The underlying therapeutic approach is based on decades of clinical research.
Yes. The project objective states the tool has proven efficacy in both clinical and web-based environments. Version 3.0 was specifically developed based on clinical trial data and up-to-date literature, indicating rigorous evidence-based development.
The project ran from May 2017 to April 2019. By project end, the app reached Version 3.0 with multilingual support, clinical trial validation, and a version fully adapted to all end-user needs (patients and caregivers). The app is described as market-ready.
The project explicitly aimed to integrate the tool into clinical practice and provide specialists with guidelines to help patients. However, specific technical integration details (EHR compatibility, API standards) are not described in the available project data.
The app targets the over 50% of 4 million European cancer patients who experience fatigue as a side effect of illness and treatment. It also serves cancer survivors, 30% of whom experience fatigue daily for up to 10 years after treatment ends.
This is a single-company project — Tired of Cancer BV, a Dutch SME and spin-out from the Helen Dowling Institute (a psycho-oncology research center). With EUR 1,171,275 in EU funding under the SME Instrument Phase 2, the company used the grant to move from a research-validated concept to a market-ready product. The 100% industry composition and SME status means decisions are fast and partnership negotiations would be direct with the founding team, not filtered through academic bureaucracy. The spin-out origin from a clinical institute gives the product scientific credibility that pure tech startups typically lack.
Tired of Cancer BV is the sole partner — reach out via untire.me or through SciTransfer for a warm introduction
Want to explore partnership, licensing, or integration opportunities with this digital cancer fatigue therapy? SciTransfer can arrange a direct introduction to the team behind the app.
